# Yonsei high-sensitivity circulating tumour DNA test for multi-cancer diagnosis and residual disease

Source: https://onco.cc/trials/yonsei-multi-cancer-mrd/  
OnCo record `yonsei-multi-cancer-mrd` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A South Korean study of a sensitive DNA sequencing blood test meant both to find several cancers and to watch for leftover disease after treatment.

## Summary

Yonsei high-sensitivity circulating tumour DNA test for multi-cancer diagnosis and residual disease (NCT07035587) is an observational study sponsored by Yonsei University. It validates a high-sensitivity sequencing method for early diagnosis and post-treatment monitoring of multiple cancers.

The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,200 participants, a start on 21 August 2024 and primary completion expected on 28 July 2029.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-29
- Registry id: NCT07035587
- Phase: observational
- Setting: People with ovarian, lung, pancreatic, colorectal, oesophageal, breast, kidney, bladder or gastric cancer and healthy controls in South Korea
- Sponsor: Yonsei University
- Enrolled: 1200

## Sources

- ClinicalTrials.gov NCT07035587: https://clinicaltrials.gov/study/NCT07035587

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/yonsei-multi-cancer-mrd.json